A novel method for detecting haemolysis, developed at the University of Oxford, has been licensed by Oxford University Innovation (OUI) to two commercial partners: Camtech Innovations and Muhdo Health.
New data shows Oxford maintains lead as university spinout landscape evolves
Applications to the 2025 Jamies are now open, for students from the Department of Chemistry and the Department of Materials.
Oxford-based biotech company Theolytics is pioneering a new frontier in cancer treatment by harnessing the power of oncolytic viruses to selectively target tumours while sparing healthy tissue.
Oxford University Innovation, in collaboration with Ernst & Young (EY), conducted an independent evaluation of England’s COVID-19 testing programme, commissioned by the UK Health Security Agency.
Oxford University Innovation has achieved the prestigious Investors in People Gold accreditation, recognising its commitment to fostering an outstanding workplace culture and a collaborative, supportive environment.
Oxford University Innovation’s Clinical Outcomes team offers validated assessment tools that capture patient experiences in gastroenterology, nutrition, and dietetics. These insights help clinicians and researchers enhance patient-centered care, improve health outcomes, and shape better healthcare policies.
Oxford Innovation Society has a dynamic new programme, expanding global investor connections and fostering deeper industry collaborations.
Oxford spinout BioFragment won a Chemovator prize at Stage Two, Europe’s largest university startup pitch, boosting their mission to revolutionise drug discovery with sustainable biocatalysis.
Oxford University Innovation (OUI) has made significant strides in research commercialisation, creating over 300 spinout companies based on research and ideas from students, staff, and alumni. Many of these companies are based on patented Intellectual Property (IP)and software from University of Oxford labs.
